High prognostic nutritional index (PNI) as a positive prognostic indicator for non‐small cell lung cancer patients with bone metastasis

Introduction Increasing evidence shows the close association between prognostic nutritional index (PNI) and overall survival (OS) of solid cancers including lung cancer. However, the role of PNI in non‐small cell lung cancer patients (NSCLC) with bone metastasis remains unclear. Objective To explore...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The clinical respiratory journal 2021-02, Vol.15 (2), p.225-231
Hauptverfasser: Xu, Shanqi, Cao, Shoubo, Geng, Jianxiong, Wang, Chunyan, Meng, Qingwei, Yu, Yan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Increasing evidence shows the close association between prognostic nutritional index (PNI) and overall survival (OS) of solid cancers including lung cancer. However, the role of PNI in non‐small cell lung cancer patients (NSCLC) with bone metastasis remains unclear. Objective To explore the prognostic role of PNI in NSCLC patients with bone metastasis. Methods A retrospective analysis of 259 initially diagnosed NSCLC with bone metastasis was conducted. Univariate and multivariate analysis were used to assess the potential prognostic roles of parameters. Results The most common symptoms initially presented were cough and chest pain. Two hundred patients (77.2%) received the treatment of bisphosphonates. Patients with low PNI were found in 154 (59.5%) patients. Median survival time for all cases was 286 days. The median OS for patients with low and high PNI was 227 and 389 days, respectively. The 6‐month, 1‐year and 2‐year survival rates for patients with low PNI were 66.2%, 29.9% and 10.4% compared to 79.0%, 52.4% and 26.7% in patients with high PNI level. On univariate analysis, female patients, non‐smokers, high PNI and systematic chemotherapy (P 
ISSN:1752-6981
1752-699X
DOI:10.1111/crj.13288